Trapping of normal EB1 ligands in aggresomes formed by an EB1 deletion mutant
© Riess et al; licensee BioMed Central Ltd. 2005
Received: 18 October 2004
Accepted: 06 April 2005
Published: 06 April 2005
EB1 is a microtubule tip-associated protein that interacts with the APC tumour suppressor protein and the p150glued subunit of dynactin. We previously reported that an EB1 deletion mutant that retains both of these interactions but does not directly associate with microtubules (EB1-ΔN2-GFP) spontaneously formed perinuclear aggregates when expressed in COS-7 cells.
In the present study live imaging indicated that EB1-ΔN2-GFP aggregates underwent dynamic microtubule-dependent changes in morphology and appeared to be internally cohesive. EB1-ΔN2-GFP aggregates were phase-dense structures that displayed microtubule-dependent accumulation around the centrosome, were immunoreactive for both the 20s subunit of the proteasome and ubiquitin, and induced the collapse of the vimentin cytoskeleton. Fractionation studies revealed that a proportion of EB1-ΔN2-GFP was detergent-insoluble and ubiquitylated, indicating that EB1-ΔN2-GFP aggregates are aggresomes. Immunostaining also revealed that APC and p150glued were present in EB1-ΔN2-GFP aggregates, whereas EB3 was not. Furthermore, evidence for p150glued degradation was found in the insoluble fraction of EB1-ΔN2-GFP transfected cultures.
Our data indicate that aggresomes can be internally cohesive and may not represent a simple "aggregate of aggregates" assembled around the centrosome. Our observations also indicate that a partially misfolded protein may retain the ability to interact with its normal physiological ligands, leading to their co-assembly into aggresomes. This supports the idea that the trapping and degradation of co-aggregated proteins might contribute to human pathologies characterised by aggresome formation.
EB1 is the prototypical member of a highly conserved family of proteins that localise to centrosomes and growing microtubule tips [1–3]. EB1 has been shown to directly interact with microtubules, the adenomatous polyposis coli (APC) tumour suppressor protein and the p150glued subunit of the dynein/dynactin microtubule motor complex [3–9]. In a previous study of a series of EB1 deletion mutants we noted that an EB1 protein lacking its N-terminal 100aa and fused at its C-terminus to GFP (EB1-ΔN2-GFP) spontaneously formed perinuclear aggregates in transfected COS-7 cells fixed and examined by immunostaining . The present study represents a further characterisation of these aggregates.
This phenomenon was considered worthy of investigation for a number of reasons. Removal of the N-terminal 100aa of EB1 to generate EB1-ΔN2-GFP neatly removes one of the major structural features of the protein, a calponin homology (CH) domain implicated in the microtubule-binding ability of EB1 [3, 9–11], while leaving the region that mediates the interactions with APC and p150glued intact. Consistent with this, EB1-ΔN2-GFP does not localise to microtubules in transfected cells whereas a GST-EB1-ΔN2 recombinant fusion protein binds to both APC and p150glued in vitro . The behaviour of EB1-ΔN2-GFP in transfected cells might therefore reveal new information about EB1 folding and function. In addition, EB1-ΔN2-GFP aggregation resembled a cellular response to the presence of misfolded, proteolytically resistant proteins termed aggresome formation [see ref  for a recent review]. Aggresomes assemble around centrosomes in a process that requires microtubules and dynein/dynactin-mediated transport [13–15]. As EB1-ΔN2-GFP retains the ability to directly interact with p150glued, an examination of the aggregation of this protein in transfected cells might yield further insight into the process of aggresome formation. Furthermore, it seemed possible that the perinuclear EB1-ΔN2-GFP aggregates might represent a structure unrelated to aggresomes and instead arise from dominant-negative effects on the normal EB1/p150glued interaction. We therefore reasoned that detailed examination of EB1-ΔN2-GFP aggregation might shed further light on the normal function of this interaction within cells.
EB1-ΔN2-GFP aggregate dynamics in living cells
EB1-ΔN2-GFP aggregates are aggresomes
The behaviour and morphology of the EB1-ΔN2-GFP structures in living cells was reminiscent of the previously reported characteristics of aggresomes [12–14]. Aggresomes form around the centrosome when the accumulation of an aberrantly folded protein exceeds the ability of the cells protein degradation apparatus to dispose of it , and they typically share certain common features. For example, like the EB1-ΔN2-GFP aggregates examined here, aggresome formation but not maintenance is microtubule dependent and in the presence of microtubule poisons newly synthesised protein is found in aggregates dispersed throughout the cytoplasm . We therefore fixed and immunostained EB1-ΔN2-GFP transfected COS-7 cells for other aggresomal markers.
EB1-ΔN2-GFP aggregates contain APC
Dynein/dynactin components are present in EB1-ΔN2-GFP aggresomes
Fractionation and Western blotting analysis of EB1-ΔN2-GFP expressing cells
These analyses were then repeated on the detergent-insoluble fraction from transfected cells. GFP immunoblotting revealed two immunoreactive bands in the insoluble fraction of cells expressing GFP (Fig. 8C). The smaller of these (arrowed) corresponded to the expected molecular weight of GFP whereas the larger (arrowhead) is consistent with the size of a monoubiquitylated GFP molecule, suggesting that a proportion of overexpressed GFP in COS-7 cells might be turned over by normal cellular mechanisms of protein degradation. Only weak immunolabelling was detected for EB1-GFP in overexposed blots (Fig. 8C, arrowed), consistent with previous observations showing endogenous EB1 to be highly soluble (1). In contrast, EB1-ΔN2-GFP was highly insoluble in transfected cell extracts (Fig. 8C). Furthermore, in addition to a major band corresponding to the expected size of EB1-ΔN2-GFP (arrowed), at least two higher molecular weight bands were also detected (arrowheads). The equal spacing between these bands suggests that these represent ubiquitylated forms of the insoluble protein, consistent with the positive ubiquitin immunoreactivity observed in EB1-ΔN2-GFP aggregates by immunostaining of transfected cells (Fig. 5 panels D-F). The presence of at least one higher molecular weight species of EB1-ΔN2-GFP was confirmed when blots were probed with the EB1 antibody and examined after overexposure (Fig. 8D, arrowhead).
EB3 and the dynein/dynactin components p50dynamitin and CDIC were essentially undetectable in the insoluble fraction of any of the transfected cell extracts (not shown). p150glued was detected in the insoluble fraction of all extracts (Fig. 8C, arrowed) but no evidence for an enrichment of insoluble p150glued in cells expressing EB1-ΔN2-GFP was found. However, two lower molecular weight species of approximately 45 and 15 kDa were specifically detected by the p150glued monoclonal antibody in the insoluble fraction of cells expressing EB1-ΔN2-GFP (Fig. 8C, arrowheads).
The data presented in this study indicate that the perinuclear aggregates formed in cells expressing EB1-ΔN2-GFP are aggresomes, although the underlying reason for their formation by this fusion protein remains unclear. Two mechanisms seem possible. First, the initial aggregation occurs as a direct consequence of the interaction between EB1-ΔN2-GFP and p150glued, perhaps coupled to aberrant retrograde transport of this complex, and aggresome formation occurs subsequent to this. A second possibility is that EB1-ΔN2-GFP misfolds, becomes refractive to proteolytic degradation and thereby triggers the formation of an aggresome. Neither EB1-GFP nor any of the other GFP-tagged EB1 deletion mutants generated in our laboratory, including those that do not interact with microtubules but retain an ability to bind APC and p150glued, form aggresomes in transfected cells . This suggests that the first possibility is less likely. Furthermore, our Western blotting analyses indicated that cell extracts from cultures transfected with the EB1-ΔN2-GFP construct contained significantly more fusion protein than those from cultures transfected with the EB1-GFP construct (Fig. 8). Since the transfection efficiency for the EB1-GFP and EB1-ΔN2-GFP constructs was similar, equal amounts of transfected cell extracts were analysed and the base expression vector used for both constructs was identical, the best explanation for the higher levels of EB1-ΔN2-GFP relative to EB1-GFP in our experiments is that EB1-GFP was turned over normally within the cell whereas EB1-ΔN2-GFP was not. This data therefore supports the second mechanism suggested above. However, if aggregation is a response to EB1-ΔN2-GFP misfolding, then the presence of both p150glued and APC in the aggregates suggests that this misfolding is partial since the binding sites for both of these proteins appears to be functional (Figs. 6 and 7; ref ). We therefore propose that EB1-ΔN2-GFP in COS-7 cells adopts a conformation where APC and p150glued binding are maintained but the fusion protein is recognised by the cellular stress response pathway for misfolded proteins, perhaps as a result of a disordered N-terminal region arising from the loss of the CH domain from the EB1 N-terminus. As this partially misfolded protein is resistant to degradation it accumulates within the cytoplasm and an aggresome is formed.
Other investigators have previously described the formation of aggresomes by a cytosolic GFP fusion protein (GFP-250) in living cells . EB1-ΔN2-GFP aggresome formation appeared to correlate well with that observed for GFP-250, particularly during aggresome assembly following nocodazole treatment and wash out. However, previous ultrastructural studies have suggested that aggresomes represent an "aggregate of aggregates" formed by an accumulation of individual particles without further coalescence into a cohesive structure [12–14]. Our time-lapse studies suggest that this is not the case with EB1-ΔN2-GFP. In our system aggresomes exhibited dynamic microtubule-dependent linear extensions. These typically resembled beads on a string with one end remaining attached to the main structure of the aggresome. Detachment and anterograde movement of individual particles from aggresomes was never seen. These observations indicate that the brighter structures in EB1-ΔN2-GFP aggresomes must be linked in some way and, since extensions were never seen to fully detach from aggresomes, this linkage is strong enough to resist the forces generated by microtubule motors. Together with our data showing that microtubules are not necessary to maintain the pericentrosomal location of pre-existing EB1-ΔN2-GFP aggresomes, this suggests that these structures possess an inherent cohesiveness and are not simply a collection of individual elements maintained in close proximity to the centrosome by dynein motor activity. At present it remains unclear whether this dynamic behaviour is a universal feature of aggresomes or is restricted to those formed by EB1-ΔN2-GFP. However, we note that associations with kinesin II have recently been described for both p150glued  and APC . Since both proteins are clearly present in EB1-ΔN2-GFP aggregates these interactions could potentially contribute to the dynamic behaviour of these structures.
Recent studies of aggresome formation by mutant CFTR and SOD proteins in cells treated with proteosome inhibitors indicated that the dynein/dynactin components CDIC, p50dynamitin and p150glued were all recruited to aggresomes [15, 25]. This raises the possibility that the p150glued observed in EB1-ΔN2-GFP-induced aggresomes was present as a normal cofactor for aggresome formation rather than as a specific EB1-ΔN2-GFP ligand. Furthermore, an increase in the amounts of p150glued and p50dynamitin in the detergent insoluble fraction of cells containing mutant SOD-induced aggresomes was reported . In our experiments no increase in the amount of insoluble full-length forms of these proteins was observed. However, in contrast to previous studies we found lower molecular weight p150glued species in the detergent-insoluble fraction of cells expressing EB1-ΔN2-GFP. The p150glued antibody used in this study recognises an epitope at the N-terminus of the protein , the same region that mediates the EB1-p150glued interaction  but distinct from the regions responsible for the interactions with other dynein/dynactin subunits . It seems possible that the bands detected in our immunoblots represent N-terminal p150glued fragments tightly bound to insoluble EB1-ΔN2-GFP and inaccessible to the proteosome. An analogous mechanism has been proposed to explain the limited proteolytic processing of NF-κB precursors, where it is suggested that a close association with a partner molecule inhibits the processive degradation of the NF-κB p50 domain . To explain the discrepancies between our data and that presented in the study of mutant SOD-induced aggresomes we therefore propose that in the latter case the dynactin complex is recruited to but not trapped within aggresomes as part of a normal cellular response, whereas in our system the aggresome-associated p150glued is tightly bound to EB1-ΔN2-GFP. Subsequent degradation of exposed regions of the molecule destroys the binding sites for p150glued-associated dynein/dynactin subunits, precluding their stable co-incorporation into the aggresome. However, binding to proteolytically-resistant EB1-ΔN2-GFP molecules preserves the p150glued fragments detected by the monoclonal antibody used in our study.
In this work we were fortunate in being able to examine aggresome formation by a defined cytosolic protein that possesses direct interactions with two other well-characterised proteins, p150glued and APC. This allowed us to show that these proteins were present in the aggresomes arising from EB1-ΔN2-GFP expression in transfected cells. Our data therefore suggests that a misfolded protein can trap its normal endogenous cellular ligands in an aggresome, potentially resulting in the degradation of these partners. This could have implications for our understanding of human diseases thought to involve protein misfolding and the formation of aggresome-like structures, such as Parkinsons disease and other neurodegenerative disorders . Our data provides a proof of principle that the pathologies characteristic of these diseases could arise in part from the inappropriate trapping and degradation of the normal physiological partners of misfolded proteins in aggresomes and inclusion bodies.
COS-7 cells were cultured and drug treatments performed as described previously . Transfections were performed using GeneJuice (Novagen) according to the manufacturers instructions. Manual counting of GFP immunostained transfected cell populations indicated that transfection efficiencies at 18 h post-transfection were consistently in the region of 60% for the GFP expression plasmid and somewhat lower at around 25% for the EB1-GFP and EB1-ΔN2-GFP expression plasmids.
Antibodies and reagents
Monoclonal antibodies specific for EB1, EB3, p150glued and p50dynamitin were obtained from Transduction Laboratories. Monoclonal antibodies specific for γ-tubulin and cytoplasmic dynein intermediate chain (CDIC) were obtained from Sigma. A mouse monoclonal antibody specific for BiP was obtained from BD Biosciences. A rat anti α-tubulin antibody was obtained from Serotec. Rabbit polyclonal antibodies against ubiquitin and the 20S proteosomal subunit were obtained from DAKO and Affiniti Research Products respectively. Rabbit polyclonal and mouse monoclonal anti-GFP antibodies were obtained from Clontech. A rabbit polyclonal antibody specific for APC (M-APC; ref ) was a kind gift from Dr Inke Nathke, University of Dundee, UK. All secondary antibodies were highly cross-adsorbed Alexa 488 and 594 conjugates obtained from Molecular Probes. Nocodazole was obtained from Sigma.
COS-7 cells were cultured and transfected on glass coverslips. Cultures were processed for immunocytochemistry using methanol fixation 18 h after transfection and imaged using a Leica TCS-SP confocal microscope as described previously . Alternatively, cells were imaged by fluorescence microscopy using a Zeiss Axiovert 200 inverted microscope coupled to an Orca II ER CCD camera controlled by AQM6 software (Kinetic Imaging, Nottingham, UK). Figures were assembled using Adobe Photoshop 7.
Time-lapse fluorescence imaging
Cells were grown and transfected in 35 mm glass-bottomed culture dishes (Iwaki brand; Asahi Techno Glass Corporation, Japan) obtained from Bibby Sterilin. 14–18 h after transfection the cell culture medium was replaced by 1.5 ml of pre-warmed medium containing 20 mM HEPES. The cells were then transferred to a Zeiss Axiovert 200 inverted microscope with the stage enclosed in a heated chamber (Solent Scientific, UK) maintained at 37°C. After 15 min equilibration cells were examined by fluorescence microscopy using a Zeiss Plan Apochromat 63X/1.4NA oil immersion lens or by fluorescence and phase contrast microscopy using a Zeiss A-Plan 40X/0.65NA dry lens. An excitation/emission filterset optimised for eGFP imaging was used for fluorescence microscopy (Chroma Technology Corp., Brattleboro, USA; filterset ID 86007). Time-lapse images were obtained using Ludl shutters and a Hamamatsu Orca II ER camera. Microscope, camera, filterwheels and shutters were controlled by AQM 6 software (Kinetic Imaging, Nottingham, UK). Typically, images were obtained using 1 × 1 binning and exposure times of less than 250 ms/frame with time-lapse intervals ranging between 5s and 30s. Time-lapse image series were saved as uncompressed AVI files then cropped, compressed and converted into Quicktime movies using Adobe ImageReady 7. Some movies are presented using an inverted greyscale colour look-up table to enhance the visibility of small structures. Particle tracking analyses were performed using Motion Analysis software from Kinetic Imaging.
Cell extractions, SDS-PAGE and Western blotting
Cells were harvested by scraping and collected by centrifugation 18 h after transfection. Cell pellets were resuspended in ice-cold PBS containing 0.1% Triton X-100, a mixture of protease inhibitors (Complete EDTA-free tablets, Roche Diagnostics, Germany), 2 mM EDTA, 50 mM sodium fluoride and 100 μM sodium orthovanadate (PBS/TX100) then incubated on ice for 5 min with occasional mixing. Insoluble and soluble fractions were separated by centrifugation at 12000 g for 5 min in a benchtop microcentrifuge. Once the supernatant was removed to a fresh tube the pellet was resuspended in a volume of PBS/TX100 equivalent to that of the removed supernatant. An equal volume of 2x concentrated SDS-PAGE sample loading buffer containing 5 mM DTT was added to both the soluble and insoluble fractions, followed by boiling for 5 min. To reduce viscosity pellet samples were passed repeatedly through a narrow gauge needle attached to a syringe before gel loading. Unused sample was snap frozen in liquid nitrogen and stored at -80°C until needed. SDS-PAGE and Western blotting were performed essentially as described previously . Blots were probed using fluorescently conjugated secondary antibodies and visualised using a Li-Cor Odyssey quantitative Western Blotting system. Equal loading of different cell extracts onto SDS-PAGE gels and subsequent transfer on to Western blotting membranes was confirmed by quantitative immunoblotting with a monoclonal β-actin antibody. Gel images were processed and converted into greyscale images using Adobe Photoshop 7. The images of some blots shown in this study have been cropped due to size considerations; only regions where no specific immunoreactivity was observed after overexposure have been removed.
This research was supported by the Medical Research Council (UK), Yorkshire Cancer Research and Cancer Research UK. We wish to thank Drs Phil Robinson and Helen Ardley of the Molecular Medicine Unit at St James's University Hospital, Leeds for useful discussions and the gift of antibody reagents.
- Morrison EE, Wardleworth B, Askham J, Markham AF, Meredith DM: EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle. Oncogene. 1998, 17: 3471-3477. 10.1038/sj.onc.1202247.View ArticlePubMed
- Mimori-Kiyosue Y, Shiina N, Tsukita S: The dynamic behaviour of the APC-binding protein EB1 on the distal ends of microtubules. Curr Biol. 2000, 10: 865-868. 10.1016/S0960-9822(00)00600-X.View ArticlePubMed
- Askham JM, Vaughan KT, Goodson HV, Morrison EE: Evidence that an interaction between EB1 and p150glued is required for the formation and maintenance of a radial microtubule array anchored at the centrosome. Mol Biol Cell. 2002, 13: 3627-3645. 10.1091/mbc.E02-01-0061.PubMed CentralView ArticlePubMed
- Su L-K, Burrell M, Hill DE, Gyuris J, Brent R, Wiltshire R, Trent J, Vogelstein B, Kinzler KW: APC binds to the novel protein EB1. Cancer Res. 1995, 55: 2972-2977.PubMed
- Juwana JP, Henderikx P, Mischo A, Wadle A, Fadle N, Gerlach K, Arends JW, Hoogenboom H, Pfreundschuh M, Renner P: EB/RP gene family encodes tubulin binding proteins. Int J Cancer. 1999, 81: 275-284. 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z.View ArticlePubMed
- Berrueta L, Tirnauer JS, Schuyler SC, Pellman D, Bierer BE: The APC-associated protein EB1 associates with components of the dynactin complex and cytoplasmic dynein intermediate chain. Curr Biol. 1999, 9: 425-428. 10.1016/S0960-9822(99)80190-0.View ArticlePubMed
- Askham JM, Moncur PM, Markham AF, Morrison EE: Regulation and function of the interaction between the APC tumour suppressor protein and EB1. Oncogene. 2000, 19: 1950-1958. 10.1038/sj.onc.1203498.View ArticlePubMed
- Ligon LA, Shelly SS, Tokito M, Holzbaur ELF: The microtubule plus-end binding proteins EB1 and dynactin have differential effects on microtubule polymerisation. Mol Biol Cell. 2003, 14: 1405-1417. 10.1091/mbc.E02-03-0155.PubMed CentralView ArticlePubMed
- Bu W, Su L-K: Characterization of functional domains of human EB1 family proteins. J Biol Chem. 2003, 278: 49721-49731. 10.1074/jbc.M306194200.View ArticlePubMed
- Gimona M, Djinovic-Carugo K, Kranewitter WJ, Winder SJ: Functional plasticity of CH domains. FEBS Lett. 2002, 513: 98-106. 10.1016/S0014-5793(01)03240-9.View ArticlePubMed
- Hayashi I, Ikura M: Crystal structure of the N-terminal microtubule-binding domain of EB1. J Biol Chem. 2003, 278: 36430-36434. 10.1074/jbc.M305773200.View ArticlePubMed
- Garcia-Mata R, Gao Y-S, Sztul E: Hassles with taking out the garbage: Aggravating aggresomes. Traffic. 2002, 3: 388-396. 10.1034/j.1600-0854.2002.30602.x.View ArticlePubMed
- Johnston JA, Ward CL, Kopito RR: Aggresomes: A cellular response to misfolded proteins. J Cell Biol. 1998, 143: 1883-1898. 10.1083/jcb.143.7.1883.PubMed CentralView ArticlePubMed
- Garcia-Mata R, Bebok Z, Sorscher EJ, Sztul ES: Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J Cell Biol. 1999, 146: 1239-1254. 10.1083/jcb.146.6.1239.PubMed CentralView ArticlePubMed
- Johnston JA, Illing ME, Kopito RR: Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil Cytoskeleton. 2002, 53: 26-38. 10.1002/cm.10057.View ArticlePubMed
- Mogensen MM, Tucker JB, Mackie JB, Prescott AR, Nathke IS: The adenomatous polyposis coli protein unambiguously localises to microtubule plus ends and is involved in establishing parallel arrays of microtubule bundles in highly polarized epithelial cells. J Cell Biol. 2002, 157: 1041-1048. 10.1083/jcb.200203001.PubMed CentralView ArticlePubMed
- Morrison EE, Moncur P, Askham JM: EB1 identifies sites of microtubule extension during neurite formation. Mol Brain Res. 2002, 98: 145-152. 10.1016/S0169-328X(01)00290-X.View ArticlePubMed
- Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker EE: Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell. 2001, 12: 1393-1407.PubMed CentralView ArticlePubMed
- Junn E, Lee SS, Suhr UT, Mouradian MM: Parkin accumulation in aggresomes due to proteosome impairment. J Biol Chem. 2002, 277: 47870-47877. 10.1074/jbc.M203159200.View ArticlePubMed
- Ardley HC, Scott GB, Rose SA, Tan NGS, Markham AF, Robinson PA: Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol Biol Cell. 2003, 14: 4541-4556. 10.1091/mbc.E03-02-0078.PubMed CentralView ArticlePubMed
- Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, DeMartino GN, Thomas PJ: Dynamic association of proteasomal machinery with the centrosome. J Cell Biol. 1999, 145: 481-490. 10.1083/jcb.145.3.481.View ArticlePubMed
- Stepanova T, Slemmer J, Hoogenraad CC, Lansbergen G, Dortland B, De Zeeuw CI, Grosveld F, van Capellen G, Akhmanova A, Galjart N: Visualisation of microtubule growth in cultured neurons via the use of EB3-GFP (end-binding protein 3-green fluorescent protein). J Neurosci. 2003, 23: 2655-2664.PubMed
- Deacon SW, Serpinskaya AS, Vaughan PS, Lopez Fanarraga M, Vernos I, Vaughan KT, Gelfand VI: Dynactin is required for bidirectional organelle transport. J Cell Biol. 2003, 160: 297-231. 10.1083/jcb.200210066.PubMed CentralView ArticlePubMed
- Jimbo T, Kawasaki Y, Koyama R, Sato R, Takada S, Haraguchi K, Akiyama T: Identification of a link between the tumour suppressor APC and the kinesin superfamily. Nat Cell Biol. 2002, 4: 323-327. 10.1038/ncb779.View ArticlePubMed
- Corcoran LJ, Mitchison TJ, Liu Q: A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr Biol. 2004, 14: 488-492. 10.1016/j.cub.2004.03.003.View ArticlePubMed
- Vaughan PS, Miura P, Henderson M, Byrne B, Vaughan KT: A role for regulated binding of p150glued to microtubule plus ends in organelle transport. J Cell Biol. 2002, 158: 305-319. 10.1083/jcb.200201029.PubMed CentralView ArticlePubMed
- Rape M, Jentsch S: Taking a bite: proteasomal protein processing. Nat Cell Biol. 2002, 4: E113-E116. 10.1038/ncb0502-e113.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.